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I
f you are diagnosed with a skin disease by one of the readers
of the Journal of Investigative Dermatology chances are that
you will be prescribed glucocorticoids, retinoids (vitamin A
analogs) or deltanoids (vitamin D analogs). Glucocorti-
coids, a class of steroid drugs, are the mainstay for the treat-
ment of skin in£ammatory conditions, e.g. dermatitis, psoriasis,
and sunburns, which are manifested as a result of hyperactive im-
mune system. Oral and topical retinoids (acitretin, tazarotene, re-
tinoic acid and adaplene) are indicated for the treatment of
psoriasis, acne and wrinkle e¡acement. Similarly, topical delta-
noids (calcipotriol, calcitriol and tacalcitol) are prescribed for
mild to moderate plaque psoriasis, severe seborrheic dermatitis
and disorders of keratinization. Further, retinoids and deltanoids
have shown e⁄cacy in limited clinical experiences with actinic
keratosis, Kaposi’s sarcoma, cutaneous T cell lymphoma (CTCL),
vitiligo, scleroderma and disorders of keratinization. Recently, a
new class of retinoid, called rexinoid (bexarotene), has been ap-
proved by the Food and Drug Administration for the treatment
CTCL.
Glucocorticoids, retinoids, rexinoids and deltanoids are small
molecular weight ligands of nuclear receptors, a superfamily of
proteins whose members directly modulate gene expression. Nu-
clear receptor proteins are modular in nature and a prototype
comprises of three functional domains. An N-terminal domain
that contains a ligand independent activation function (AF-1), a
central DNA binding domain (DBD) consisting of two C2-C2
type zinc ¢ngers that target the receptor to speci¢c DNA se-
quences and a C-terminal multifunctional domain containing
the ligand binding domain (LBD), a ligand dependent activation
function (AF-2) and a hydrophobic zipper type dimerization mo-
tif (Nagpal et al, 1993). These pharmaceutical targets are therefore
ligand-dependent transcription factors that include receptors for
steroids (glucocorticoids, estrogen, progesterone, androgen and
mineralocorticoids), retinoids, vitamin D3 and thyroid hormone.
The nuclear receptor superfamily can be broadly classi¢ed into
two subfamilies, namely type I and type II. Type I nuclear recep-
tors include classical steroid receptors (e.g., glucocorticoid recep-
tor, GR), which function as homodimers and bind to inverted
repeats present in the promoter regions of responsive genes. On
the other hand retinoic acid receptors (RARs), retinoid X recep-
tors (RXRs), thyroid hormone receptors (TRs), vitamin D re-
ceptor (VDR), peroxisome proliferator activated receptors
(PPARs), farnesoid X receptor (FXR) and liver X receptors
(LXRs) are members of the type II subfamily (Burris, 2001). At
the molecular level, these receptors function as a heterodimer
with an obligate partner, RXR, and bind to DNA elements that
are direct repeats of the sequence 50 -AGG/TTCA-30, present in
the upstream regions of responsive genes. In the type II subfam-
ily, RARs, VDR, TRs, and PPARs are known to regulate gene
expression in two di¡erent ways. As a heterodimer with RXR,
they either induce the expression of certain genes by binding to
the response elements present in their promoters or they down-
regulate the expression of other genes by antagonizing the enhan-
cer action of transcription factors, such as AP1, NF-kB, NF-IL6
or NF-AT (for references, see Pinette et al, 2003). These positive
and negative gene regulatory events explain the normalization of
keratinocyte di¡erentiation, inhibition of keratinocyte prolifera-
tion and immunomodulatory activities observed as a result of
the application of RAR or VDR ligands in vitro as well as in vivo
in psoriatic lesions (DiSepio et al, 1999). The subtle modulation of
gene expression by ligand-activated nuclear receptors ultimately
culminates in normalization of the pathologic state.
LXRwas identi¢ed as an orphan nuclear receptor from a liver
cDNA library and was so named because of its abundant expres-
sion in the liver. Two LXR subtypes, namely LXRa and LXRb
have been identi¢ed that are encoded by di¡erent genes (for re-
ferences, see Peet et al, 1998). LXRa shows a relatively restricted
pattern of expression (limited to small intestine, liver, kidney,
spleen, adipose tissue and adrenals), whereas LXRb is expressed
ubiquitously (Peet et al, 1998). Both LXRs are also expressed in
human keratinocytes and fetal rat epidermis, whereas, LXRb is
the predominant form in adult mouse epidermis (Komuves et al,
2002). Biochemical ligand-screening assays with compounds in-
volved in cholesterol metabolism resulted in the identi¢cation of
oxysterols as endogenous ligands of LXR. Since synthetic LXR
ligands are nonoxysterols in chemical structure, in line with the
nomenclature of retinoids, rexinoids and deltanoids, LXR li-
gands (natural and synthetic) would be referred to as oxynoids
in this commentary. Pharmacophore analysis revealed that unlike
the classical steroid, retinoid, thyroid hormone and vitamin D re-
ceptors, LXRs bound to their cognate ligands (oxynoids) with
relatively low a⁄nity (with binding constant, Kd of 4150 nM)
(Spencer et al, 2001). Like some of the other members of the type
II nuclear receptor subfamily, LXRs form obligate heterodimers
with RXRs and bind to promoter sequences consisting of direct
50 -AGG/TTCA-30 repeats separated by 4 nucleotides. LXRs func-
tion as cholesterol sensors since upon activation by oxynoids,
LXRs induce the expression of genes involved in cholesterol ab-
sorption (e.g., cholesterol transporters ABCA1, ABCG5 and
ABCG8 in enterocytes), cholesterol transport from peripheral tis-
sues (ABCA1, ABCG1 and Apo E in macrophages) and cholester-
ol catabolism (Cyp7A1 in liver). Therefore, LXRs are considered
to be promising therapeutic targets for the development of eLiX-
iRs for the treatment of hypercholesterolemia and cardiovascular
(CV) disease (for references, see Lu et al, 2001). Recently, they
were also shown to decrease glucose levels in a murine model of
type II diabetes (Cao et al, 2002). However, a major impediment
in the development of an oxynoid as a therapeutic agent for CV
disease and type II diabetes is its ability to induce hypertriglycer-
idemia by up-regulating liver fatty acid synthesis via the induc-
tion of SREBP-1c gene expression (Lu et al, 2001).
In this issue, Fowler et al demonstrate a new potential therapeu-
tic utility of oxynoids and show that topical application of oxy-
sterols, 22R-hydroxycholesterol and 25-hydroxycholesterol as
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well as a nonsteroidal synthetic ligand (GW 3965; Spencer et al,
2001) inhibit irritant and allergic contact dermatitis in vivo. Fow-
ler et al describe for the ¢rst time that LXR ligands also possess
potent anti-in£ammatory activities since they reduced in£amed
ear weight and thickness in a mice model of TPA-induced cuta-
neous in£ammation or oxazolone-induced allergic dermatitis.
The anti-in£ammatory e¡ect was comparable to that of 0.05%
clobetasol, a potent topical corticosteroid. The observation de-
monstrating the anti-in£ammatory action of topically applied
oxynoids also provides a way to exploit the therapeutic potential
of LXRs by circumventing the hypertriglyceridemia side-e¡ect
by using compounds with low systemic absorption for the treat-
ment of cutaneous in£ammatory diseases. The anti-in£ammatory
activities of GR, RAR andVDR result from their negative gene
regulatory actions (transrepression) and dissociated ligands that
are selective for transrepression, in contrast to transactivation,
have been developed for GR and RAR (Nagpal et al, 1995; Lin
et al, 2002). Inhibition of cytokine (IL-1, IL-2, IL-6, IL-8, INF-a
and IFN-g) gene expression and protein production provides a
molecular basis of anti-in£ammatory e¡ect exerted by glucocor-
ticoid, retinoid and deltanoid compounds. Therefore, logically
LXRs may display anti-in£ammatory activities by negatively reg-
ulating cytokine gene expression. Oxysterols exhibit unique im-
munomodulatory activities, since they induced the expression of
IL-1b and TNF-a in resting monocytes/macrophages that have
not been challenged with in£ammatory insults, whereas they in-
hibited the expression of IL-1a and TNF-a in systems that mimic
the in£ammatory scenario by producing copious levels of these
cytokines as a result of LPS stimulation, thus indicating that even
their antiatherogenic e¡ects could in part be mediated by LXR-
dependent transrepression events. It remains to be seen whether
oxynoids also a¡ect T-cell activation and elaboration of other cy-
tokines by activated cells (T-cells, monocytes/macrophages, anti-
gen presenting cells and keratinocytes) that collaborate to
produce a cutaneous in£ammatory response. Fowler et al demon-
strate that 22R-hydroxycholesterol treatment inhibited the pro-
duction of pro-in£ammatory cytokines IL-1a and TNF-a in
in£amed skin of both irritant and allergic contact dermatitis
models. Clearly, it appears that the oxynoid-mediated transactiva-
tion of gene expression is important for their e¡ect on cholesterol
metabolism and homeostasis, whereas the transrepression of cyto-
kine gene expression appears to be involved in their anti-in£am-
matory activities (Fig 1). However, whether oxynoids also inhibit
the AP1/NF-kB/NF-AT signal transduction pathways remains to
be seen. Since LXR ligands have also been shown to increase ker-
atinocyte di¡erentiation and reduce their proliferation in vitro and
in vivo, oxynoids may also be of therapeutic value in psoriasis, dis-
orders of keratinization, actinic keratosis and skin cancers.
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Figure1. Schematic representation of regulation of gene expression by oxynoids. Ligands after binding to LXR-RXR heterodimers up-regulate
(þ ) the expression of oxynoid responsive genes such as ATP-binding cassette (ABC) containing transporters (ABCA1, ABCG5 and ABCG8), Apo E
(apolipoprotein E), CETP (cholesterol ester transfer protein) and SREBP-1c (sterol regulatory element-binding protein-1c). They also down-regulate (^)
the induced expression of IL-1a and TNF-a by as yet unknown mechanisms. Induction of SREBP-1c appears to be responsible for hypertriglyceridemia
seen in vivo by oxynoids. Positive gene regulatory activities (except for SREBP-1c induction) explain the e¡ects of oxynoids on cholesterol metabolism and
homeostasis and their potential use in the treatment of CVdiseases. Negative gene regulatory activities highlight the anti-in£ammatory actions of oxynoids
and their potential use for the treatment of cutaneous in£ammatory diseases.
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